Arsenic trioxide (As 2 O 3 ) is an effective therapy in acute promyelocytic leukemia (APL), but its use in other malignancies is limited by the higher concentrations required to induce apoptosis. We have reported that trolox, an analogue of a-tocopherol, increases As 2 O 3 -mediated apoptosis in a variety of APL, myeloma and breast cancer cell lines, while nonmalignant cells may be protected. In the present study, we extended previous results to show that trolox increases As 2 O 3 -mediated apoptosis in the P388 lymphoma cell line in vitro, as evidenced by decrease of mitochondrial membrane potential and release of cytochrome c. We then sought to determine whether this combination can enhance antitumor effects while protecting normal cells in vivo. In BDF 1 mice, trolox treatment decreased As 2 O 3 -induced hepatomegaly, markers of oxidative stress and hepatocellular damage. In P388 tumor-bearing mice, As 2 O 3 treatment prolonged survival, and the addition of trolox provided a further significant increase in lifespan. In addition, the combination of As 2 O 3 and trolox inhibited metastatic spread, and protected the tumor-bearing mice from As 2 O 3 liver toxicity. Our results suggest, for the first time, that trolox might prevent some of the clinical manifestations of As 2 O 3 -related toxicity while increasing its pro-apoptotic capacity and clinical efficacy in hematological malignancies.
Introduction
Arsenic trioxide (As 2 O 3 ), first used in traditional Chinese medicine, is highly effective in the treatment of patients with acute promyelocytic leukemia (APL). [1] [2] [3] Although the precise mechanism of action of As 2 O 3 in APL is unclear, in vitro studies reported that As 2 O 3 leads to cellular redox status perturbation, cellular signaling modulation, differentiation, growth inhibition and apoptosis. 4 Clinically achievable concentrations, that is between 1 and 2 mM of As 2 O 3 , induce apoptosis and inhibit growth of various malignant cells, including multiple myeloma and human T lymphotropic retrovirus type I-associated adult T-cell leukemia cells. [5] [6] [7] Recently, Rousselot et al. 8 documented in vivo activity of arsenic in the treatment of multiple myeloma using a SCID mouse xenotransplantation model. In another xenotransplantation model, As 2 O 3 (3.75 mg/kg) induced a significant reduction of L540Cy Hodgkin tumors. 9 Subsequent in vivo studies characterized the effectiveness of arsenic in various hematological malignancies, and multiple phase I/II clinical trials are underway to evaluate its feasibility, safety and potential efficacy. Arsenic has also been tested in nonhematological cancer. Using an orthotopic prostate metastasis model, As 2 O 3 alone provided a dose-dependent inhibition of both primary and metastatic lesions, although an increased survival rate was only obtained in the group treated with the combination of As 2 O 3 and buthionine sulfoxamine (BSO), an inhibitor of g-glutamyl cysteine synthase. 10 In spite of these and other studies showing sensitivity to arsenic treatment in vitro and in vivo, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] the degree of sensitivity has been consistently less than in APL cells, and clinical trials in different hematological malignancies and solid tumors have had mixed results. [15] [16] [17] [18] These initial investigations suggest that arsenic trioxide, as a single agent, may have limited clinical activity outside APL. Therefore, combinations with other agents should be explored to increase antitumor efficacy and the therapeutic index of As 2 O 3 .
Several compounds have been reported to increase As 2 O 3 -mediated apoptosis in vitro. 5, 19, 20 BSO modulates the cellular glutathione system and can significantly potentiate the effects of As 2 O 3 , converting arsenic-resistant cell lines to a sensitive phenotype. 21, 22 Although in vivo effects have been reported for this combination, 23 the observed additive toxicity may not be selective for cancer cells, and BSO itself has not been successfully developed for clinical use. Ascorbic acid (AA), a key antioxidant molecule, augments the toxicity of As 2 O 3 in vitro, 24, 25 but controversy exists regarding its mechanism of action, 26 and its potential for utility in the clinic is under study. We have demonstrated recently that trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) enhances the sensitivity of APL to As 2 O 3 in vitro. We extended these results to NB4, an arsenic-resistant subclone of NB4, the IM9 multiple myeloma cell line and a variety of breast cancer cell lines. 27 In all these malignant cell lines, treatment with As 2 O 3 and trolox increases intracellular oxidative stress, as evidenced by elevated heme oxygenase-1 (HO-1) protein levels, JNK activation and protein and lipid oxidation. Importantly, we found that trolox could protect non-malignant cells from As 2 O 3 -mediated cytotoxicity in vitro, suggesting that it may diminish or overcome the adverse effects associated with As 2 O 3 monotherapy in vivo, potentially increasing the therapeutic index. As a presumed antioxidant, trolox has been used to mitigate the toxic effects of several compounds in animal models. Trolox reduced liver necrosis in a model of hepatic ischemia reperfusion in rats 28 and decreased streptozotocin-induced liver and kidney damage in mice. 29 In this study, we addressed the effects of As 2 O 3 and trolox on the viability of lymphoma P388 cells in vitro and in a mouse tumor model. We also investigated mechanisms underlying the pro-apoptotic properties of this combination, and its potential toxic effects in mice. We show that the combination of As 2 O 3 and trolox decreases arsenic toxicity in non-tumor and tumorbearing mice, while increasing the survival time and limiting the metastatic spread in mice bearing P388 lymphoma cells.
Materials and methods

Growth assays
P388 cells (provided by Dr Jing, Mount Sinai Medical Center, New York) were treated with various concentrations of As 2 O 3 þ /À 100 mM trolox for 6 days. Viable cells were counted by trypan blue exclusion on days 1, 3 and 6. Logarithmic growth phase was maintained at a density lower than 1 Â 10 6 cells/ml through dilution as required, and media þ /À treatment was replaced every third day.
Annexin V/propidium iodide staining
Cells were stained with annexin-V-FITC and propidium iodide (PI) in binding buffer according to manufacturer's (BD Pharmingen, San Diego, CA, USA) and analyzed on a FACScan (Becton Dickinson, San Jose, CA, USA). Apoptotic cells (Annexin V positive/PI negative) were quantified using the CellQUEST software (Becton Dickinson).
Detection of the mitochondrial membrane potential (DC m )
Changes in DC m were determined with the J-aggregate-forming lipophilic cationic fluorochrome JC-1 (Molecular Probes, Eugene, OR, USA). Cells were incubated with 2.5 mg/ml JC-1 for 15 min. Cells were washed two times with PBS, resuspended in phosphate buffered solution (PBS), and analyzed on a FACScan. Data were analyzed and expressed as the ratio of mean fluorescence intensity between FL2 (polarized, dimeric) and FL1 (depolarized, monomeric) fluorescence.
Preparation of S-100 fractions and assessment of cytochrome c release Cells were harvested, washed with ice-cold PBS and resuspended in five volumes of buffer (75 mM NaCl, 8 mM Na 2 HPO 4 , 1 mM NaH 2 PO 4 , 1 mM EDTA, 350 mg/ml digitonin, 1 mM dithiothreitol, 0.1 mM. phenylmethylsulfonyl fluoride, 10 mM aprotinin and 10 mM leupeptin). After 30 min on ice, the cells were centrifuged twice at 750 g, 10 min at 41C. Cytosolic S-100 fractions (supernatants) were obtained by centrifugation at 100 000 g for 60 min at 41C. Cytochrome c release into the S-100 fraction for each condition was assessed by western blot analysis.
Western blotting
Livers were disrupted by a Polytron homogenizer (Brinkmann, Westbury, NY, USA). Debris was removed by centrifugation at 700 g for 15 min, followed by centrifugation of the supernatant twice at 14 400 g for 15 min and finally at 100 000 Â g for 1 h at 41C. Proteins were separated and probed as described previously 27 with cytochrome c (1:500: BD Pharmigen), HO-1 (1:1000, Stressgen), and HSP70 (1:5000: Stressgen). Immunostaining for b-actin confirmed equal protein loading.
Cytochrome c oxidase (CcO) activity and cellular ATP levels Mouse liver mitochondria were isolated using a mitochondria isolation kit (Sigma). CcO activity was calculated based on the rate of oxidation of ferrocytochrome c (decrease in absorbance at 550 nm). Ferrocytochrome c concentrations were determined using a kit (Sigma), with values expressed as mmol/min/mg mitochondrial protein. The intracellular ATP concentration was determined with a luminescent ATP detection kit (ATPLite; PerkinElmer Life Sciences) and was measured using a multiplate reader. ATP was calculated from a standard curve and was expressed as mM ATP/mg wet tissue.
In vivo toxicity experiments
All procedures conformed to the NIH guidelines for the care and use of laboratory animals, and were approved by the McGill University Animal Care Committee. BDF 1 mice (Charles River Laboratories, Wilmington, MA, USA) were randomly divided into eight groups of five mice. Each group received trolox (2.5, 10, 20 or 50 mg/kg), As 2 O 3 (7.5 mg/kg) or the combinations of trolox and As 2 O 3 interperitoneally. On alternate days for a total of 14 injections. Animals were weighed every other day. One day after the last dose of arsenic, blood was collected by cardiac puncture. Serum was separated and total protein levels, glucose content, activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (AKP) were assayed using commercially available kits. Mice were killed by cervical dislocation. Liver was extracted and washed in ice-cold isotonic saline solution and weighed. Liver samples were fixed in 10% phosphate-buffer formalin (pH 7.4), embedded in paraffin, sectioned, stained with hematoxylin-eosin, and examined under bright field microscope by a pathologist. Lymphocyte infiltration and number of binucleated cells were quantified in 10 random 0.159 mm 2 fields/sample.
In vivo anti-tumor experiments
P388 cells were injected i.p. in DBA/2 mice (Charles River Laboratories, Wilmington, MA, USA). After 15 days, cells were collected from the peritoneum, washed and resuspended in PBS. For experiments, 0.1 ml containing 2 Â 10 6 cells obtained from the ascites was inoculated i.p. in BDF 1 mice. Mice were randomly divided into six groups each with eight mice. After 24 h, each group was given saline, As 2 O 3 (7.5 or 10 mg/kg) and trolox (50 mg/kg) alone or in combination i.p. On alternate days for a total of 14 injections. The percentage increase in lifespan (ILS) over control was calculated as follows: ILS% ¼ 5T/ C%À100, where T is the test mean survival time, and C is the control mean survival time. Macroscopically visible lesions were counted in the liver, stomach, pancreas and intestine by a pathologist blinded to the treatment groups. Sections of liver were stained for hematoxylin and eosin to verify that the counted visible liver lesions were indeed liver metastases.
Statistical analysis
Significance was determined by analysis of variance followed by Newman-Keuls post-tests using Prism version 3.0 (GraphPad software, San Diego, CA, USA). The combination index (CI), an indication of the interaction between two drugs, was determined by the formula a/A þ b/B ¼ 1, where a is the IC 50 of As 2 O 3 þ trolox at a concentration b; A is the IC 50 of As 2 O 3 ; and B is the IC 50 of trolox. According to this formula, when CIo1, the interaction is synergistic, when CI ¼ 1, the interaction is additive, and when CI41, the interaction is antagonistic. 30 Effects of trolox plus As 2 O 3 in vitro and in vivo Z Diaz et al
Results
Trolox significantly enhances As 2 O 3 -induced apoptosis of murine lymphoma P388 cells
Based on our finding of synergy in NB4, AsR2, IM9 and a variety of breast cancer cells lines, 27 we first investigated whether trolox would increase the in vitro efficacy of As 2 O 3 in a lymphoma cell line for which there is an established animal model. As Figure 1a shows, treatment of P388 cells for 6 days with 2 and 4 mM As 2 O 3 reduced the viable cell number by 19.0 and 51.7% of control, respectively (Po0.001). Thus, P388 cells are less sensitive to As 2 O 3 than some leukemic cell lines, in which 0.5 and 1 mM As 2 O 3 are sufficient to induce a similar effect. Trolox (100 mM) alone had no effect on cell number at any time point. However, if the cells were treated with 2 or 4 mM As 2 O 3 and 100 mM trolox in combination, 41.2 and 81.3% reductions in cell number were observed (Po0.001, when compared to As 2 O 3 alone at either dose). In all cases, trypan blue-positive cells were less than 3%. A difference was also seen at 72 h, where addition of trolox enhanced the action of 4 mM As 2 O 3 by decreasing cell number by 29% compared to As 2 O 3 alone. The CI value was determined to be 0.619, documenting a synergistic interaction between As 2 O 3 and trolox. A variety of complementary techniques were then performed to analyze whether the observed growth inhibitory effects were the result of the induction of apoptosis in P388 cells. Using annexin V/propidium iodide staining, we found that 24% of the cells treated with 2 mM As 2 O 3 were apoptotic after 48 h (Figure 1b ). This percentage was nearly doubled when trolox was added. Similarly, the addition of trolox to 4 mM As 2 O 3 increased apoptosis from 33.2 to 58.5% (Po0.001). Consistently, control and cells treated with trolox exhibited JC-1 orange fluorescence due to the formation of JC-1 aggregates, indicating that the mitochondria were polarized (Figure 1c ). Exposure to As 2 O 3 induced a very rapid decline in DC m , as revealed by complete loss of JC-1 orange fluorescence and a shift to JC-1 green fluorescence due to the formation of JC-1 monomers. Consistently, a dosedependent decrease of DC m was observed in the cells treated with the combination of As 2 O 3 and trolox. As a consequence of the decreased mitochondrial membrane potential, cytochrome c may be released from the mitochondria, providing another marker of apoptosis. As shown in Figure 1d , cytoplasmic cytochrome c content was increased when trolox and As 2 O 3 were used in combination at both As 2 O 3 doses. Thus, our data indicate that trolox increases As 2 O 3 -induced apoptosis in P388 cells. In our previous work, we demonstrated that trolox decreases cytotoxicity of As 2 O 3 in mouse embryonic fibroblasts. 27 In addition, we have determined that trolox protects the nontumorigenic murine hepatocyte AML cells from As 2 O 3 toxicity in vitro (data not shown), suggesting that synergistic toxicity of the combination could be specific to tumor cells. To test this hypothesis in vivo, we first conducted toxicological studies to define the maximum tolerable dose of trolox in BDF 1 mice.
Trolox treatment was well tolerated and not toxic at the doses studied (2.5, 10, 20, and 50 mg/kg), as indicated by assessment of body weight over the course of the study; the average body weight did not differ significantly from the control animals in any treatment group. The higher dose approaches its maximum solubility limit in 300 ml, the maximum volume that can be injected in mice intraperitoneally.
Liver damage has been reported to be a marker of arsenic toxicity in different experimental animals.
31,32 Therefore, we asked whether trolox could affect As 2 O 3 -associated hepatocellular damage in vivo. Mice were randomly divided into groups of five mice and treated with two doses of trolox and a dose of As 2 O 3 (7.5 mg/kg) reported to be moderately toxic. 24 None of the animals exhibited discomfort or obvious distress throughout the duration of the experiment. No significant differences in weight were observed in any of the treated groups compared to control. As depicted in Figure 2a , moderate hepatomegaly was observed in the As 2 O 3 -treated group. The average liver weights in the control and trolox groups were quite similar, with an average of 1.0770.14 g, while in the As 2 O 3 -treated group, average liver weight was increased to 1.5370.35 g (Po0.05). However, in the groups treated with the combination of As 2 O 3 and trolox, the hepatomegaly was abrogated, with an average liver weight of 1.1070.1 g (Po0.05 As 2 O 3 vs. As 2 O 3 þ trolox).
When hepatocellular injury occurs, the associated plasma membrane leakage can be detected biochemically by assaying aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity in serum. Figures 2b and c show that both (Figure 3a) , characterized by hepatocellular degeneration, inflammatory infiltrates composed of fibrinous exudates and polymorphonuclear leukocyte aggregates, and areas with focal necrosis. A marked increase in binucleated cells was observed, suggesting regeneration of hepatocytes after acute toxicity. We tested whether the addition of trolox would modify this cellular pattern of toxicity. Lymphocyte foci and binucleated cells were counted in randomly selected fields by a pathologist blinded to the treatment groups. A significant decrease in lymphocyte infiltration and binucleated cells was observed after treatment with As 2 O 3 and trolox compared to As 2 O 3 alone (Figures 3b and c) . These results indicate that trolox significantly protects hepatocytes from As 2 O 3 -mediated toxicity.
Trolox decreases As 2 O 3 -mediated oxidative stress and ameliorates the As 2 O 3 -mediated decrease in cellular metabolic rate in BDF 1 mice
Oxidative damage may be a key mechanism by which arsenic mediates its toxic effects. Because trolox decreases As 2 O 3 -induced liver toxicity, we hypothesized that the addition of trolox reduces hepatocellular oxidative stress induced by As 2 O 3 . HO-1, an oxidative stress-responsive protein, 33 was not detected in the liver of control animals or animals treated with trolox alone, but was markedly induced by As 2 O 3 . The addition of trolox significantly decreased As 2 O 3 -mediated HO-1 induction in all the animals (Figure 4a ). The 70 kDa heat shock proteins (HSP-70 family) are important for protein folding and help to protect cells from stress. HSP-70 expression has been used as an indicator of As 2 O 3 exposure in different experimental models. 34 As depicted in Figure 4b , HSP-70 protein levels were enhanced in the livers of As 2 O 3 -treated group, while they were decreased to near basal levels when the animals were treated with the combination of As 2 O 3 and trolox. The HSP70 antibody recognizes the inducible form of HSP-70 (HSP-72) and the constitutive form HSP-73, explaining the basal levels in the control and trolox-treated groups.
Thus, having established that As 2 O 3 induces liver oxidative stress, and that the addition of trolox significantly restores hepatocellular redox homeostasis, we further analyzed whether the hepatocellular metabolic rate was affected by this combination. Sulfhydryl groups in many enzyme systems react with arsenicals, which may result in a block of the Krebs cycle, interrupting oxidative phosphorylation, which in turn causes marked depletion of ATP stores. 7 The activity of cytochrome c oxidase in the liver is considered to be a good metabolic marker for functional activity of cells. Therefore, we asked whether (Figure 4d ). These results again show protective effects of trolox on arsenic-mediated liver toxicity.
Trolox increases As 2 O 3 -mediated antitumor effects in BDF 1 mice bearing lymphoma P388 cells while protecting against liver toxicity
On the basis of the in vitro potency and favorable in vivo toxicity profiles, As 2 O 3 and trolox were evaluated for in vivo antitumor efficacy in mice bearing P388 murine lymphoma tumors. The dose selection for As 2 O 3 (7.5 and 10 mg/kg body weight) was based on the relatively low toxicity seen in our initial study of non-tumor-bearing mice. Trolox was given at 50 mg/kg, which was not toxic in our preliminary results but approached the maximum solubility. As shown in Figure 5a , As 2 O 3 treatment prolonged survival, with median survival times of 20 and 18 days for 7.5 and 10 mg/kg As 2 O 3 , respectively, as compared to 14 days for controls (Po0.001). The median survival time for animals treated with the combination of As 2 O 3 and trolox was further prolonged to 24.5 and 22 days compared to that of with As 2 O 3 alone (Po0.001). Treatment with 7.5 mg/ kg As 2 O 3 provided a 46.4% ILS (Figure 5b ). When this dose was combined with trolox, we observed a 73.5% ILS. Animals treated with 10 mg/kg As 2 O 3 , experienced an increased life span of only 28.6% (Po0.001). We observed moderate weight loss and lethargy in these mice (data not shown), suggesting that this dose is toxic. However, the addition of trolox doubled the increase in lifespan of 10 mg/kg As 2 O 3 alone without evidence of increased toxicity. The effects of the combination of As 2 O 3 and trolox on tumor metastases were profound. At the time of killing or death due to tumor progression, metastases were present in all of the eight (100%) saline-treated control animals as seen macroscopically and in histological sections (Figure 5c and data not shown). Treatment with 7.5 and 10 mg/kg As 2 O 3 reduced the number of animals with metastases to 62.5 and 37.5%, respectively. The Animal deaths were tabulated and Kaplan-Meier curves were generated to depict percent survival (a). Increase in lifespan of treated animals relative to controls was calculated (b). Macroscopically visible lesions were counted in liver, stomach, pancreas and intestine in all the animals (c). Asterisks indicate significant differences from As 2 O 3 -treated groups (*Po0.05, **Po0.01, ***Po0.001). Number signs indicate significant differences (Po0.001) from controls.
Effects of trolox plus As 2 O 3 in vitro and in vivo Z Diaz et al incidence of metastases was significantly decreased to 37.5 and 12.5% when trolox was combined with 7.5 and 10 mg/kg As 2 O 3 (Po0.001). We examined livers from tumor-bearing mice to analyze whether trolox could also modulate As 2 O 3 -mediated oxidative stress and its effects on the metabolic rate of these animals. We found that the non-treated, tumor-bearing animals had a higher baseline of liver oxidative stress than non-tumorbearing mice, as demonstrated by an increase in HO-1 protein levels (first lane of Figure 6a , compared to Figure 4a) . Interestingly, treatment with trolox alone decreased the hepatic oxidative stress. As 2 O 3 treatment caused some further increase in HO-1 expression at both 7.5 and 10 mg/kg (Figure 6a and data not shown). However, addition of trolox significantly decreased HO-1 protein levels at both doses of As 2 O 3 studied. Similarly, HSP70 expression was consistently increased by As 2 O 3 , and this effect was reduced by trolox ( Figure 6b ). We then explored the effects of the As 2 O 3 and trolox combination on hepatic metabolic rate using assays of CcO and ATP as shown before. Consistently, CcO activity ( Figure 6c ) and ATP stores ( Figure 6d ) were markedly reduced in the animals treated with As 2 O 3 , but significantly restored in the animals treated with the combination of As 2 O 3 and trolox. In addition, serum ALT levels were less elevated when As 2 O 3 was given with trolox (data not shown). These results show that although tumorbearing mice have baseline liver damage, consistent with our data for non-tumor-bearing mice, trolox protects the liver from arsenic-mediated toxicity.
Discussion
Although activity in many malignant cell lines requires concentrations of As 2 O 3 that are not clinically achievable, our previous work identified trolox as a compound that might have a dual role depending on the cellular microenviroment. In malignant cells, trolox synergizes with As 2 O 3 to increase its toxicity while in non-malignant cells, trolox decreases As 2 O 3 -mediated cellular damage. This is the first report showing that the combination of As 2 O 3 and trolox in vivo targets malignant cells and limits cancer metastases, while decreasing damage to normal cells. In this study, we used the mildly As 2 O 3 -resistant P388 lymphoma cell line to assess the potential synergy of As 2 O 3 and trolox in vitro and in vivo. We found that the combination of As 2 O 3 and trolox enhanced growth inhibition and apoptosis of P388 cells. These data support a synergistic effect of trolox in enhancing As 2 O 3 toxicity consistent with previously published work in NB4, AsR2, IM9, MCF7, T47D and MDA-231 cells. 27 These in vitro effects provided the rationale for experiments using the P388 lymphoma cell line to determine how trolox would affect As 2 O 3 activity and toxicity in vivo. We first performed in vivo studies with As 2 O 3 and trolox alone or in combination to investigate whether trolox would affect arsenic toxicity in BDF 1 mice. We observed As 2 O 3 -induced liver toxicity, which has been previously reported to involve tissue necrosis and other histological and biochemical changes in several animal models. 35 In these non-tumor-bearing mice, we found that trolox protects normal hepatic cells from As 2 O 3 toxicity. This is the first study to report in vivo protective effects of trolox on arsenic-induced hepatotoxicity, although several studies have demonstrated its efficacy in preventing toxicity of other metals. 36 In addition, studies have shown that a trolox derivative (U-83836E) appeared to be beneficial in reducing lipid peroxidation products and in partially preventing the decrease in glutathione and antioxidant enzymes induced by methanol in liver, serum 37 and brains 38 of rats. Lower doses of trolox than used in the present study clearly reduced methylmercury-induced toxicity in rats. 39 These studies suggest that trolox may decrease toxicity associated with a broad spectrum of compounds.
Based on our in vitro results and the favorable in vivo toxicity profile, we evaluated As 2 O 3 and trolox for in vivo antitumor efficacy in the peritoneal P388 murine lymphoma model. This model was used to test the combination of ascorbic acid and arsenic, which also was reported to be effective in vitro in various cell lines. In addition, this model has been used to test the effects of different antineoplastic drugs. [40] [41] [42] Trolox doses ranging from 2 to 100 mg/kg have been used in rats and rabbits. [43] [44] [45] The intraperitoneal route was chosen in an attempt to avoid the potential confounding factors on As 2 O 3 absorption through the gastrointestinal tract and to compare parenteral arsenic effects with previous reports in the literature. 46, 47 We showed that the addition of trolox to As 2 O 3 given to mice bearing P388 lymphoma cells significantly increased their survival time. It has been reported, using the same model, that ascorbic acid enhanced antitumor properties of As 2 O 3.
24 Dai et al. observed an increase in survival time with the combination of AA and As 2 O 3 , although they used a lower dose of As 2 O 3 (5 mg/kg), which did not increase the lifespan of the mice as a single agent. Using 7.5 mg/kg As 2 O 3 , we obtained a significant prolongation of survival that was markedly improved by the addition of trolox. Most notably, our studies show the potential for As 2 O 3 and trolox given as a combination to limit metastases. It remains critical to reconcile these two opposite effects of the As 2 O 3 and trolox combination, that is, a cooperative action of As 2 O 3 and trolox against lymphoma growth and metastases with the concomitant protection by trolox of normal cells in vivo.
Our data suggest that trolox may behave as a pro-oxidant in cancer cells exposed to As 2 O 3 , while having antioxidant properties in normal cells. Therapeutic enhancement by antioxidants is counterintuitive to the apparent role of ROS in apoptosis. However, the pro-or antioxidant effects of many redox-active compounds may vary substantially as a function of the cellular redox microenvironment and models employed. For example, it has been proposed that the selectivity of certain chemotherapeutic agents to cancer cells may be due, in part, to the relatively low concentrations of antioxidant enzymes documented in some malignant cells. 48, 49 It is noteworthy that normal cells in general are more efficient in eliminating ROS than malignant cells. Furthermore, a specific ROS or its intracellular localization could be the critical determinant of cell death or survival. Finally, it has been demonstrated that vitamin E 50 may modulate tumor cell permeability by altering levels of lipid peroxidation in surface membranes, raising the possibility that trolox differentially augments As 2 O 3 uptake by malignant cells.
Our observation of reduced toxicity of As 2 O 3 in vivo, delayed death in mice bearing P388 tumor cells and reduction of metastatic spread in this model suggests that the combined use of As 2 O 3 and trolox may increase the therapeutic index of arsenic and possibly decrease the development of secondary tumors in patients with advanced lymphoma and other malignancies.
